Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 3
2017 2
2019 1
2020 1
2022 2
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors.
Moreno L, Teira P, Croop JM, Gerber NU, André N, Aerts I, Gros Subias L, De Wilde B, Bautista F, Turpin B, Kunduri S, Hamidi A, Lawrence T, Streby KA. Moreno L, et al. Among authors: streby ka. Front Pediatr. 2023 May 24;11:1183295. doi: 10.3389/fped.2023.1183295. eCollection 2023. Front Pediatr. 2023. PMID: 37292376 Free PMC article.
Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology Group.
Streby KA, Parisi MT, Shulkin BL, LaBarre B, Bagatell R, Diller L, Grupp SA, Matthay KK, Voss SD, Yu AL, London WB, Park JR, Yanik GA, Naranjo A. Streby KA, et al. Pediatr Blood Cancer. 2023 Aug;70(8):e30418. doi: 10.1002/pbc.30418. Epub 2023 May 18. Pediatr Blood Cancer. 2023. PMID: 37199022 Clinical Trial.
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor.
Lerman BJ, Li Y, Carlowicz C, Granger M, Cash T, Sadanand A, Somers K, Ranavaya A, Weiss BD, Choe M, Foster JH, Pinto N, Morgenstern DA, Rafael MS, Streby KA, Zeno RN, Mody R, Yazdani S, Desai AV, Macy ME, Shusterman S, Federico SM, Bagatell R. Lerman BJ, et al. Among authors: streby ka. J Clin Oncol. 2023 Jan 20;41(3):508-516. doi: 10.1200/JCO.22.01273. Epub 2022 Oct 7. J Clin Oncol. 2023. PMID: 36206505
Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation.
Currier MA, Sprague L, Rizvi TA, Nartker B, Chen CY, Wang PY, Hutzen BJ, Franczek MR, Patel AV, Chaney KE, Streby KA, Ecsedy JA, Conner J, Ratner N, Cripe TP. Currier MA, et al. Among authors: streby ka. Oncotarget. 2017 Mar 14;8(11):17412-17427. doi: 10.18632/oncotarget.14885. Oncotarget. 2017. PMID: 28147331 Free PMC article.
First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial.
Streby KA, Currier MA, Triplet M, Ott K, Dishman DJ, Vaughan MR, Ranalli MA, Setty B, Skeens MA, Whiteside S, Yeager ND, Haworth KB, Simpson K, Conner J, Cripe TP. Streby KA, et al. Mol Ther. 2019 Nov 6;27(11):1930-1938. doi: 10.1016/j.ymthe.2019.08.020. Epub 2019 Sep 10. Mol Ther. 2019. PMID: 31570234 Free PMC article. Clinical Trial.
VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.
Currier MA, Eshun FK, Sholl A, Chernoguz A, Crawford K, Divanovic S, Boon L, Goins WF, Frischer JS, Collins MH, Leddon JL, Baird WH, Haseley A, Streby KA, Wang PY, Hendrickson BW, Brekken RA, Kaur B, Hildeman D, Cripe TP. Currier MA, et al. Among authors: streby ka. Mol Ther. 2013 May;21(5):1014-23. doi: 10.1038/mt.2013.39. Epub 2013 Mar 12. Mol Ther. 2013. PMID: 23481323 Free PMC article.
13 results